vemurafenib
FDA Grants New Indication for Tecentriq Plus Cotellic and Zelboraf for Advanced Melanoma
The new combination increased PFS to a median of 15.1 months compared with placebo plus cobimetinib and vemurafenib ...
AUGUST 4, 2020
FDA Approves First Treatment for Erdheim-Chester Disease
The first FDA-approved treatment for ECD, Zelboraf is indicated to treat patients whose cancer cells have ...
NOVEMBER 7, 2017
New Data Confirm Cobimetinib-Vemurafenib Combo as a New Standard
Long-term data from the pivotal coBRIM trial, which explored combination cobimetinib (Cotellic, Genentech) and ...
SEPTEMBER 14, 2016
Load more